Name

OPIA Technologies

Legal name

OPIA Technologies SAS

Website

https://opiatech.com

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

1–10 employees

Ownership category

akta.pro rank

Product category

Ophthalmic Medical Devices

NAICS

Ophthalmic Goods Manufacturing (339115), Surgical and Medical Instrument Manufacturing (339112), Surgical Appliance and Supplies Manufacturing (339113)

SIC

Ophthalmic Goods (3851), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Dry Eye & Ocular Surface Devices (Meibography, Tear Osmolarity, IPL, Thermal Pulsation) (HLAHAJAF)

Keywords

• Ophthalmic medical devices
• Ocular surface diagnostics
• Tear film sampling
• Ocular iontophoresis
• Conjunctival impression cytology

Headquarters

HQ city

Paris

HQ country

France

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Supply Chain, Operations, Marketing or Sales

Revenue model

1. Medical Device Sales: Sale of proprietary ophthalmic medical devices including EYEPRIM, TEARPRIM, and IONTOFOR-VET product lines. Products are classified medical devices sold to healthcare providers and veterinary clinics.
2. R&D and Regulatory Services: Provides R&D and regulatory services for medical devices companies. Encompasses support from early-stage idea or proof-of-concept to pilot production or volume manufacturing, including regulatory and quality conformity services.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels1 record

Core offering

OPIA Technologies designs, manufactures and sells proprietary ophthalmic medical devices for sampling ocular surface components (conjunctiva, tear film) and for non-invasive ocular drug delivery via iontophoresis. Its marketed products include EYEPRIM™, TEARPRIM™, IONTOFOR-VET and IONTOFOR-VET Electrode, all backed by proprietary patents and an ISO 13485 quality management system. The company also provides R&D and regulatory services for medical device and pharmaceutical companies.

Product overview

OPIA Technologies is a medical device company developing a portfolio of ophthalmic devices for sampling ocular surface components and non-invasive ocular drug delivery, based on proprietary patents. The product portfolio comprises four distinct medical devices: EYEPRIM™ (conjunctival impression device for cell/biomarker sampling, Class I sterile), TEARPRIM™ (tear film sampling device, Class IIa sterile), IONTOFOR-VET (complete iontophoresis administration set for veterinary PACK-CXL with Riboflavin), and IONTOFOR-VET Electrode (veterinary iontophoresis administration set compatible with multiple drug classes). EYEPRIM™ and TEARPRIM™ are CE-marked and FDA-exempt sampling tools for ocular surface diagnosis, while IONTOFOR-VET products are veterinary iontophoresis delivery systems. The company also has two pipeline devices under development for ocular surface and retinal disorders, and provides R&D and regulatory services for other medical device companies.

Differentiator

Problem solved

Functional benefit

Brands

• EYEPRIM™: Sterile medical device for conjunctival impressions enabling analysis of cells and biomarkers for diagnosis of ocular surface disorders such as dry eye, allergies, or infections.
• TEARPRIM™
• IONTOFOR-VET
• IONTOFOR-VET Electrode

Products and services

• EYEPRIM™ EYEPRIM™ is a sterile Class I medical device designed to perform conjunctival impressions of the living eye, enabling collection of cells and biomarkers for cytology, cytometry, and PCR analysis to diagnose ocular surface disorders such as dry eye, allergies, and infections. It is CE 0051 (IMQ) certified under directive 93/42/CEE and FDA exempted from Premarket Authorization (21CFR880.6025). Used by ophthalmologists and in clinical studies in the US and Europe.
• TEARPRIM™ TEARPRIM™ is a sterile Class IIa medical device designed to sample the tear film, enabling analysis of tear components for diagnosing ocular surface disorders such as dry eye and allergies. It replaces tedious and non-standardized capillary tube and Schirmer strip techniques with a nearly painless, minimally invasive collection of high-quantity tears. It is CE 0051 (IMQ) certified under directive 93/42/CEE and was developed in collaboration with Quinze-Vingts Hospital.
• IONTOFOR-VET IONTOFOR-VET is a complete veterinary administration set that delivers Riboflavin (Ribovet) into the corneal stroma via iontophoresis for the PACK-CXL (photo-activated chromophore corneal cross-linking) procedure treating infectious keratitis. It includes a corneal applicator, a vial of Ribovet and a vacuum syringe, and reduces the soaking phase from 30 minutes to 5 minutes without removing the epithelium. For use with the I-ON CXL current generator and a UV-A 370nm light source. Veterinary use only.
• IONTOFOR-VET Electrode IONTOFOR-VET Electrode is a veterinary administration set that allows iontophoresis delivery of a wide array of products — including antibiotics (Vancomycin, Amikacin, Ciprofloxacin, etc.), antifungals (Ketoconazole, Miconazole), antivirals (Foscarnet, Ganciclovir) and anti-inflammatories (Dexamethasone, Methylprednisolone) — into the corneal stroma. Includes a corneal applicator and vacuum syringe. Must be used with the I-ON CXL current generator. Veterinary use only.
• R&D and Regulatory Services for Medical Devices R&D and regulatory services for medical device and pharmaceutical companies, spanning the full device lifecycle from early-stage idea or proof-of-concept to pilot production or volume manufacturing, including regulatory and quality conformity support under the company's ISO 13485 quality management system.

Quantifiable outcome

• IONTOFOR-VET reduces PACK-CXL soaking phase from 30 minutes to 5 minutes
• +2 more outcomes

Named customers2 records

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Five partnerships are on record, tiered core and minor.

• JB TECNICScoreStrategic or Co-development PartnerJB TECNICS is a worldwide group specialized in tool manufacturing and clean room molding for the medical industry. OPIA Technologies benefits from a privileged relationship with JB TECNICS for developing turnkey solutions for medical devices manufacturing. This partnership provides OPIA with manufacturing capabilities and clean room facilities essential for medical device production.
• Vision Institute (Paris)coreStrategic or Co-development PartnerOPIA Technologies is located at the Vision Institute in Paris, a major ophthalmology research center. This provides proximity to research expertise and clinical collaboration opportunities.
• Quinze-Vingts HospitalcoreStrategic or Co-development PartnerTEARPRIM was developed in close collaboration with Quinze-Vingts Hospital and ophthalmologists. EYEPRIM originated from an idea suggested by Christophe Baudouin, MD, PhD, Chairman of Department of Ophthalmology III at Quinze-Vingts Hospital and Research team leader at Vision Institute Team S12, Inserm-UPMC Research Center 968.
• Christophe BaudouinminorStrategic or Co-development PartnerChristophe Baudouin, MD, PhD, Chairman of Department of Ophthalmology III at Quinze-Vingts Hospital, suggested the original idea for EYEPRIM device. He is Research team leader at Vision Institute, Team S12, Inserm-UPMC Research Center 968.
• IMQ (Istituto Marchio Qualità)minorOthersIMQ is the notified body (CE 0051) that certified OPIA Technologies' medical devices EYEPRIM and TEARPRIM under directive 93/42/CEE.

Scale indicators3 records

Recent moves6 records

Expansion highlights4 records

Emerging players

• CXL Ophthalmics: CXL Ophthalmics focuses on corneal cross-linking and infectious keratitis therapeutics. It is an emerging peer in the same PACK-CXL / cross-linking space where OPIA's IONTOFOR-VET iontophoresis approach is positioned.

Direct peers

• I-ON CXL: I-ON CXL manufactures the iontophoresis current generator that pairs with OPIA's IONTOFOR-VET administration set for PACK-CXL. It is a complementary co-development partner and the closest comparable in veterinary iontophoresis-based cross-linking.
• I-MED Pharma: I-MED Pharma offers a portfolio of dry eye and ocular surface diagnostic and therapeutic products sold to ophthalmologists and optometrists. It overlaps with OPIA in standardized ocular surface disorder management tools for clinical practices.
• TearLab Corporation: TearLab developed the TearLab Osmolarity System, a point-of-care diagnostic for dry eye that quantifies tear osmolarity. It is directly comparable to OPIA's EYEPRIM and TEARPRIM as a device-based dry eye diagnostic aimed at ophthalmologists and optometrists.
• Rapid Pathogen Screening (RPS Diagnostics): RPS commercializes InflammaDry, a rapid point-of-care MMP-9 test for ocular surface inflammation. It competes with OPIA's EYEPRIM as an alternative diagnostic workflow for identifying ocular surface disease in eye care practices.

Broad incumbents

• Haag-Streit Group: Haag-Streit produces ophthalmic diagnostic instruments (slit lamps, imaging, perimeters) used by ophthalmologists and optometrists. It is a broad incumbent in clinical ophthalmic instrumentation that competes for the same clinical-practice budget as OPIA's devices.
• Bausch + Lomb: Bausch + Lomb is a diversified ophthalmic company with pharmaceutical, surgical, and consumer vision care products including dry eye and ocular surface franchises. It represents a broad incumbent with adjacent diagnostic and device exposure to OPIA's markets.
• Tomey Corporation: Tomey manufactures ophthalmic diagnostic equipment including specular microscopes, topographers, and ocular surface analyzers sold to clinics and hospitals. It is comparable as a supplier of ophthalmic diagnostic devices that practitioners purchase alongside OPIA's sampling products.
• Johnson & Johnson Vision: Johnson & Johnson Vision operates a large ophthalmic device and pharmaceutical franchise spanning surgical, contact lens, and dry eye categories. It is a broad incumbent that competes for the same ophthalmologist and optometrist customers as OPIA.
• Alcon: Alcon is a global ophthalmic medical device and pharmaceutical incumbent with broad dry eye, surgical, and vision care portfolios. It is a broad incumbent whose diagnostic and surgical device lines overlap with OPIA's ocular surface and ophthalmic device offerings.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about OPIA Technologies